Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study

Clin Infect Dis. 2022 Aug 24;75(1):e916-e919. doi: 10.1093/cid/ciab1009.


Following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination, people living with human immunodeficiency virus (HIV, PLWH) had lower surrogate virus neutralization test response (P = .03) and a trend toward lower immunoglobulin G (IgG) response (P = .08), particularly among those with lower CD4+ T-cell counts and who received the BNT162b2 vaccine. Study of the impact of supplemental vaccine doses among PLWH is needed.

Keywords: COVID-19; HIV; SARS-CoV-2; immune response; vaccination.

Publication types

  • Observational Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • Case-Control Studies
  • HIV
  • Humans
  • Immunoglobulin G
  • Neutralization Tests
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccination
  • Viral Vaccines*


  • Antibodies, Viral
  • Immunoglobulin G
  • RNA, Messenger
  • Viral Vaccines
  • BNT162 Vaccine